- Conditions
- Genital Diseases, Genital Diseases, Male, Genital Neoplasms, Male, +8 more
- Locations
-
- Precision Point Specialty LLC PPS Analytics, a Specialty Networks LLC Company Cleveland, Ohio, United States
Clinical trial condition
Metastatic Hormone-sensitive Prostate Cancer
Explore clinical trials studying Metastatic Hormone-sensitive Prostate Cancer. Study availability and eligibility vary by location and protocol.
20 public trials
6 recruiting studies
Metastatic Hormone-sensitive Prostate Cancer trial results
NCT07451002
- Conditions
- Genital Diseases, Genital Diseases, Male, Genital Neoplasms, Male, +8 more
- Locations
-
- Centre Francois Baclesse Caen, France
Recruiting
A Study of Pasritamig (JNJ-78278343) in Combination With Other Agents for Metastatic Prostate Cancer
NCT05818683
- Conditions
- Metastatic Castration-resistant Prostate Neoplasms, Metastatic Hormone-sensitive Prostate Cancer
- Locations
-
- Florida Cancer Specialists Sarasota, Florida, United States
- Start Midwest Grand Rapids, Michigan, United States
- Washington University School Of Medicine St Louis, Missouri, United States
- Perlmutter Cancer Center at NYU Langone Brooklyn Brooklyn, New York, United States
NCT06334120
- Conditions
- Metastatic Hormone-sensitive Prostate Cancer, Non-metastatic Castration-resistant Prostate Cancer
- Locations
-
- Multiple locations Multiple Locations, South Korea
- Conditions
- Genital Diseases, Genital Diseases, Male, Genital Neoplasms, Male, +8 more
- Locations
-
- CH Bayonne Bayonne, France
- Institut Bergonié Bordeaux, France
- CHP Brest - Pasteur Brest, France
- Hôpital Henri-Mondor Créteil, France
NCT06991556
- Conditions
- Metastatic Hormone-sensitive Prostate Cancer
- Locations
-
- University of California San Diego - Moores Cancer Center La Jolla, California, United States
- Saint Johns Cancer Institute Santa Monica, California, United States
- Rocky Mountain Cancer Centers Denver, Colorado, United States
- Yale Cancer Center New Haven, Connecticut, United States
Not Yet Recruiting
Evaluation of the Efficacy of Darolutamide Triplet Therapy in Patients With Metastatic Hormone-sensitive Prostate Cancer
NCT07031258
- Conditions
- Darolutamide (DARO) in Combination With Androgen-deprivation Therapy (ADT) and Docetaxel (DOC), Metastatic Hormone-sensitive Prostate Cancer
- Locations
-
Not specified
- Conditions
- Metastatic Hormone-sensitive Prostate Cancer, Parkinson Disease 4, Autosomal Dominant Lewy Body
- Locations
-
- Alaska Clinical Research Center ( Site 0274) Anchorage, Alaska, United States
- Providence Alaska Medical Center ( Site 0276) Anchorage, Alaska, United States
- City of Hope Medical Center ( Site 0217) Duarte, California, United States
- UCLA Hematology/Oncology - Santa Monica ( Site 0241) Los Angeles, California, United States
Completed
PSMA PET/CT-Based Multimodal Model for Predicting Response to First-Line Therapy in mHSPC.
NCT07428642
- Conditions
- Genital Diseases, Genital Diseases, Male, Genital Neoplasms, Male, +9 more
- Locations
-
- The First Affiliated Hospital of Wenzhou Medical University Wenzhou, Zhejiang, China
NCT00309985
- Conditions
- Metastatic Hormone-sensitive Prostate Cancer
- Locations
-
- Providence Cancer Center Anchorage, Alaska, United States
- Fairbanks Cancer Treatment Center at Fairbanks Memorial Hospital Fairbanks, Alaska, United States
- Mayo Clinic Hospital Phoenix, Arizona, United States
- Mayo Clinic Scottsdale Scottsdale, Arizona, United States